Oppenheimer analyst Suraj Kalia maintained a Buy rating on TransMedics Group (TMDX) today and set a price target of $25.00. The company’s shares closed last Tuesday at $16.20.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 3.5% and a 52.1% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TransMedics Group with a $20.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.23 and a one-year low of $10.10. Currently, TransMedics Group has an average volume of 126.8K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TMDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
